- ImmunoGen (IMGN +9.8%) bounces back from early losses to trade sharply higher.
- Early weakness was likely attributable to Morgan Stanley, where analysts downgraded the shares to Underweight with a $9.50 price target citing trouble with IMGN901.
- See also: IMGN signs third licensing agreement with Novartis.
ImmunoGen shakes off Morgan Stanley downgrade to trade higher
From other sites
at CNBC.com (Dec 19, 2014)
at CNBC.com (Dec 2, 2014)
at CNBC.com (Sep 8, 2014)
at CNBC.com (Aug 14, 2014)
at CNBC.com (Jun 25, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs